Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019)
- 2000-03-01
- European Journal of Clinical Nutrition 54(3)
- K. Arunachalam
- H. Gill
- R. Chandra
- PubMed: 10713750
- DOI: 10.1038/sj.ejcn.1600938
Abstract
Objective: To determine the effects of dietary consumption of Bifidobacterium lactis (strain HN019, DR10TM) on natural immunity.
Design: A randomized, double blind, placebo-controlled clinical trial.
Setting: Janeway Medical Centre, Memorial University, St Johns, Newfoundland.
Subjects: Twenty-five healthy elderly volunteers (median age 69 y; range 60-83 y).
Interventions: Twelve control subjects consumed 180 ml low-fat/low-lactose milk twice daily for a period of 6 weeks; 13 test subjects consumed milk supplemented with 1.5x1011 colony-forming units of B. lactis twice daily. Indices of natural immunity, including interferon production, phagocytic capacity and phagocyte-mediated bactericidal activity, were determined via peripheral blood at 0, 3, 6 and 12 weeks post-trial commencement.
Results: Subjects who consumed milk containing B. lactis for 6 weeks produced significantly enhanced levels of interferon-alpha, upon stimulation of their peripheral blood mononuclear cells in culture, in comparison to the placebo control group who received milk alone. There were also significant increases in polymorphonuclear cell phagocytic capacity among test group subjects, following consumption of milk supplemented with B. lactis, while individuals who consumed B. lactis-supplemented milk or milk alone showed enhanced phagocyte-mediated bactericidal activity.
Conclusions: The results demonstrate that dietary consumption of B. lactis HN019 can enhance natural immunity in healthy elderly subjects, and that a relatively short-term dietary regime (6 weeks) is sufficient to impart measurable improvements in immunity that may offer significant health benefits to consumers.
Sponsors: Financial support for this project was provided by the New Zealand Dairy Board.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium animalis subsp. lactis HN019 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium animalis subsp. lactis HN019 | Improved Phagocytic Capacity of Polymorphonuclear Cells | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis HN019 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis | Improved Phagocytic Capacity of Polymorphonuclear Cells | Beneficial | Moderate |
Bifidobacterium lactis | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis B420 | Enhanced Interferon Production | Beneficial | Large |
Bifidobacterium lactis B420 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis B420 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis BI-04 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis BI-04 | Improved Phagocytic Capacity of Polymorphonuclear Cells | Beneficial | Moderate |
Bifidobacterium lactis BI-04 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis Bi-07 | Enhanced Interferon Production | Beneficial | Large |
Bifidobacterium lactis Bi-07 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis Bi-07 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis BL818 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis BL818 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis BL818 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis BLA80 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis BLA80 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis BLA80 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis BLC-1 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis BLC-1 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis BLC-1 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis BS01 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis BS01 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis BS01 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis DSM 15954 | Enhanced Interferon Production | Beneficial | Large |
Bifidobacterium lactis DSM 15954 | Improved Ex Vivo Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis DSM 15954 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis HA-194 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis HA-194 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis HA-194 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis HN019 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis HN019 | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis HN019 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis ISS Bif | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis ISS Bif | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis ISS Bif | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis MAK16B42L | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis MAK16B42L | Increased Interferon-Alpha Production | Beneficial | Moderate |
Bifidobacterium lactis MAK16B42L | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis R101-8 | Enhanced Phagocytic Function | Beneficial | Moderate |
Bifidobacterium lactis R101-8 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis R101-8 | Increased Interferon Production | Beneficial | Moderate |
Bifidobacterium lactis SD-5219 | Enhanced Interferon Production | Beneficial | Large |
Bifidobacterium lactis SD-5219 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis SD-5219 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |
Bifidobacterium lactis UABla-12 | Enhanced Interferon Production | Beneficial | Large |
Bifidobacterium lactis UABla-12 | Improved Phagocyte-mediated Bactericidal Activity | Beneficial | Large |
Bifidobacterium lactis UABla-12 | Increased PMN Cell Phagocytic Capacity | Beneficial | Large |